Ellingson Rachel's most recent trade in Biolife Solutions Inc was a trade of 6,876 Common Stock done . Disclosure was reported to the exchange on March 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 6,876 | 49,825 (0%) | 0% | - | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2025 | 1,566 | 12,397 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2025 | 1,566 | 3,131 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.46 per share. | 20 Feb 2025 | 491 | 11,906 (0%) | 0% | 103.5 | 50,799 | Common Stock |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 5,572 | 12,623 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,572 | 5,572 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 5,572 | 0 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.00 per share. | 14 Feb 2025 | 1,792 | 10,831 (0%) | 0% | 101 | 180,992 | Common Stock |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 11,264 | 42,949 (0%) | 0% | - | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 1,419 | 7,291 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 1,419 | 2,837 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.82 per share. | 06 Mar 2024 | 445 | 6,846 (0%) | 0% | 125.8 | 55,990 | Common Stock |
| Zimmer Biomet Holdings Inc | Ellingson Rachel | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 1,762 | 6,460 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Ellingson Rachel | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 1,762 | 0 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Ellingson Rachel | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.80 per share. | 25 Feb 2024 | 588 | 5,872 (0%) | 0% | 128.8 | 75,734 | Common Stock |
| Zimmer Biomet Holdings Inc | Ellingson Rachel | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 4,697 | 4,697 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 4,256 | 4,256 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,046 | 0 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,046 | 4,864 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.73 per share. | 21 Feb 2023 | 361 | 4,503 (0%) | 0% | 124.7 | 45,028 | Common Stock |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,187 | 30,828 (0%) | 0% | - | Common Stock | |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 259 | 20,641 (0%) | 0% | - | Common Stock | |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 341 | 20,382 (0%) | 0% | - | Common Stock | |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 14,730 | 19,730 (0%) | 0% | - | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 531 | 0 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 531 | 3,791 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.43 per share. | 01 May 2022 | 167 | 3,624 (0%) | 0% | 122.4 | 20,446 | Common Stock |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 1,708 | 1,708 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 1,014 | 1,014 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 12,891 | 12,891 | - | - | Employee Stock Option (right to buy) | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 515 | 3,260 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 515 | 515 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 177.27 per share. | 01 May 2021 | 162 | 3,098 (0%) | 0% | 177.3 | 28,718 | Common Stock |
| Biolife Solutions Inc | Rachel Ellingson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 5,000 | 5,000 (0%) | 0% | - | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2021 | 156 | 2,803 (0%) | 0% | 0 | Common Stock | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2021 | 156 | 0 | - | - | Restricted Stock Units | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 163.91 per share. | 26 Feb 2021 | 58 | 2,745 (0%) | 0% | 163.9 | 9,507 | Common Stock |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,479 | 8,479 | - | - | Employee Stock Option (right to buy) | |
| Zimmer Biomet Holdings Inc | Rachel Ellingson | SVP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 156 | 156 | - | - | Restricted Stock Units |